Boothbay Fund Management, LLC Arcus Biosciences, Inc. Call Options Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$13.69 - $18.01 $454,508 - $597,932	33,200 New	33,200 $507,000
Q4 2023 Feb 14, 2024	SELL	$13.43 - $19.63 $513,026 - $749,866	-38,200 Reduced 24.81%	115,800 $2.21 Million
Q3 2023 Nov 14, 2023	SELL	$17.62 - $23.54 $7.68 Million - $10.3 Million	-435,600 Reduced 73.88%	154,000 $2.76 Million
Q2 2023 Aug 14, 2023	BUY	$16.97 - $22.03 $7.58 Million - $9.85 Million	446,900 Added 313.17%	589,600 $12 Million
Q1 2023 May 15, 2023	BUY	$15.96 - $23.15 $2.28 Million - $3.3 Million	142,700 New	142,700 $2.6 Million
Q2 2022 Aug 15, 2022	SELL	$17.23 - $37.73 $315,309 - $690,459	-18,300 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$28.92 - $41.83 $529,236 - $765,489	18,300 New	18,300 $578,000

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.